glp-1 drug news today 2025 Agonists Market Report 2025-2033, By Product, Molecule, and Geo What's next for GLP-1 innovation:

Role of receptor phosphorylation in desensitization and internalization of the secretin receptor

Triple-Hormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial

More research is needed to better understand the consequences of elevated blood alcohol levels on the rest of the body, Mehal says

The approval came after clinical trials involving 3,477 patients (2,519 on Zepbound and 958 on a placebo): Patients taking 5mg of Zepbound lost 15% of their body weight (study 1) Patients taking 10mg of Zepbound lost 19.5% (study 1) and 12.8% (study 2) of their body weight Patients taking 15mg of Zepbound lost 20.9% (study 1) and 14.7% (study 2) of their body weight Patients taking the placebo lost 3.1% (study 1) and 3.2% (study 2) of their body weight Zepbound was released to market on December 5, 2023, with six available dosages available to those with a prescription: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg